

## Waters introduces new peptide multi-attribute method workflow

19 March 2021 | News

### End-to-end streamlined LC-MS workflow for analyzing monoclonal antibodies and other protein and peptide-based drugs

Waters Corporation has introduced a new peptide multi-attribute method (MAM) workflow for the Waters™ [BioAccord™ LC-MS System](#), enabling drug development, manufacturing, and QC scientists to monitor efficacy and safety through the analysis of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs.

The peptide MAM workflow for the BioAccord System monitors for:

- Product variants
- Product degradation and impurities
- Process stability-indicating modifications

[Quality Assistance](#), a leading contract research organization based in Belgium, uses the Waters BioAccord System as part of [a comprehensive portfolio of mass spectrometry services](#) it provides to the pharmaceutical industry.

The BioAccord System pairs the ACQUITY™ UPLC™ I-Class Plus with the ACQUITY RDa™ Mass Detector featuring SmartMS™ enabled usability features. The system offers a wide range of users with varying MS experience, industry-leading automated setup and self-diagnosis capability delivered through modern instrument control software and an intuitive user interface, all within a small footprint. In addition to peptide MAM, the BioAccord System also features workflows for other routine analyses of biotherapeutics: peptide mapping, intact/subunit mass analysis, released glycan profiling and oligonucleotide mass confirmation.